Catalyst Event
OliX Pharmaceuticals Inc (226950) · Other
From Akros SCHK HK-Korea Biotech Index (ASHKBIO)
5/14/2026, 12:00:00 AM
CEO Dong Ki Lee is scheduled to present research on the company's RNAi platform for ophthalmic diseases at the TIDES USA 2026 conference on May 14, 2026; a 5% price impact is estimated due to potential clinical data updates, scheduled.
Korean Translation
이동기 대표이사가 2026년 5월 14일 'TIDES USA 2026' 컨퍼런스에서 안과 질환용 RNAi 플랫폼 연구 성과를 발표할 예정이며, 데이터 기대감에 따른 약 5%의 주가 영향이 예상됨.
Related Recent Events
3SBio Inc (1530) · Earnings Release
First half 2026 earnings results are expected to be released around August 26, 2026, expected. High importance is estimated due to the significant impact of previous earnings growth on stock volatility.
8/26/2026, 12:00:00 AM
3SBio Inc (1530) · Other
The ex-dividend date for the final cash dividend of HKD 0.25 per share for the fiscal year 2025 is July 21, 2026, scheduled.
7/21/2026, 12:00:00 AM
Sino Biopharmaceutical Ltd (1177) · Other
The ex-dividend date for the proposed final dividend of HKD 0.05 per share is 2026-06-24, which is estimated to have a price impact of ≥1% scheduled.
6/24/2026, 12:00:00 AM
Innovent Biologics Inc (1801) · Other
Innovent will present obesity pipeline data at the ADA Scientific Sessions on June 5-8, 2026; this low-impact event is scheduled
6/5/2026, 12:00:00 AM
Giant Biogene Holding Co Ltd (2367) · Other
Ex-dividend date of 2026-06-01 for final and special dividends, scheduled. (Estimated Low impact as dividend is standard).
6/1/2026, 12:00:00 AM
D&D Pharmatech Inc (347850) · Other
The 48-week top-line results from the Phase 2 clinical trial of 'DD01', a MASH treatment, are scheduled to be presented at the European Association for the Study of the Liver (EASL) Congress 2026 (May 27-30) as a Late-Breaking Abstract; high impact is estimated due to the significant market potential for MASH treatments, which is expected.
5/27/2026, 12:00:00 AM